EcoDrugPlus

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSCLAG00000001775
Gene Symbol: PSMB4
2 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSCLAG00000011138
Gene Symbol: PSMB5
2 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSCLAG00000011492
Gene Symbol: PSMB6
2 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSCLAG00000013548
Gene Symbol: PSMB7
2 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCLAG00000006990
Gene Symbol: PSMB8
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSCLAG00000007918
Gene Symbol: PSMB9
2 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSCLAG00000015382
Gene Symbol: PSMD2
3 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSCLAG00000000632
Gene Symbol: PSMD4
2 Cross references
293 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSCLAG00000014074
Gene Symbol: PSMC1
2 Cross references
308 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSCLAG00000005494
Gene Symbol: PSMC2
2 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSCLAG00000013916
Gene Symbol: PSMC3
2 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSCLAG00000001058
Gene Symbol: PSMC4
2 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).